tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Nephritis, Hereditary D009394 1 associated lipids
Skin Diseases, Papulosquamous D017444 2 associated lipids
Scalp Dermatoses D012536 11 associated lipids
Collagen Diseases D003095 2 associated lipids
Pruritus Vulvae D011539 1 associated lipids
Phyllodes Tumor D003557 1 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Anemia, Refractory D000753 3 associated lipids
Pulmonary Veno-Occlusive Disease D011668 1 associated lipids
Tongue Diseases D014060 2 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Cholecystolithiasis D041761 2 associated lipids
Budd-Chiari Syndrome D006502 1 associated lipids
Idiopathic Interstitial Pneumonias D054988 1 associated lipids
Acneiform Eruptions D017486 3 associated lipids
Rheumatoid Nodule D012218 1 associated lipids
Granuloma Annulare D016460 1 associated lipids
Hypoplastic Left Heart Syndrome D018636 1 associated lipids
Incontinentia Pigmenti D007184 2 associated lipids
Discitis D015299 2 associated lipids
Arthritis, Reactive D016918 3 associated lipids
Akinetic Mutism D000405 1 associated lipids
Pityriasis Lichenoides D017514 2 associated lipids
Histiocytosis D015614 2 associated lipids
Mastocytosis, Cutaneous D034701 1 associated lipids
Mediastinal Emphysema D008478 1 associated lipids
Invasive Pulmonary Aspergillosis D055744 1 associated lipids
Netherton Syndrome D056770 1 associated lipids
Coccidioidomycosis D003047 2 associated lipids
Meningitis, Fungal D016921 1 associated lipids
Panniculitis, Lupus Erythematosus D015435 1 associated lipids
Lymphohistiocytosis, Hemophagocytic D051359 1 associated lipids
Rupture D012421 2 associated lipids
Lichen Nitidus D017513 1 associated lipids
Eye Infections, Fungal D015821 2 associated lipids
Hypoalbuminemia D034141 1 associated lipids
Porokeratosis D017499 1 associated lipids
Dermatitis, Perioral D019557 4 associated lipids
Scleritis D015423 3 associated lipids
Multiple Endocrine Neoplasia Type 2a D018813 1 associated lipids
Intertrigo D007402 1 associated lipids
Impetigo D007169 3 associated lipids
Nocturnal Myoclonus Syndrome D020189 1 associated lipids
Pterygium D011625 3 associated lipids
Amyloid Neuropathies D017772 1 associated lipids
Mucinoses D017520 2 associated lipids
Carcinoma, Merkel Cell D015266 2 associated lipids
Nocturia D053158 1 associated lipids
Failed Back Surgery Syndrome D055111 3 associated lipids
Malacoplakia D008287 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Blackham A and Griffiths RJ The effect of FK506 and cyclosporin A on antigen-induced arthritis. 1991 Clin. Exp. Immunol. pmid:1718639
Carobbi A et al. Effect of splenectomy in combination with FK 506 and 15-deoxyspergualin on cardiac xenograft survival. 1991 Transplant. Proc. pmid:1703704
Fukuda T et al. Inhibition of antigen-induced late asthmatic response and bronchial hyperresponsiveness by cyclosporin and FK 506. 1991 Int. Arch. Allergy Appl. Immunol. pmid:1718889
Murase N et al. FK 506 prevents spontaneous diabetes in the BB rat. 1991 Transplant. Proc. pmid:1703705
Meiser BM et al. Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. 1991 Lancet pmid:1719321
Watanabe K et al. Donor bone marrow cell facilitates induction of tolerance to kidney allografts in dogs treated with fractionated lymphoid irradiation and FK 506. 1991 Transplant. Proc. pmid:1703706
Jorgensen WL Rusting of the lock and key model for protein-ligand binding. 1991 Science pmid:1719636
Jain AB et al. Pharmacokinetics of cyclosporine and nephrotoxicity in orthotopic liver transplant patients rescued with FK 506. 1991 Transplant. Proc. pmid:1721274
McMichael J et al. Evaluation of a novel "intelligent" dosing system for optimizing FK 506 therapy. 1991 Transplant. Proc. pmid:1721275
Ali Shah I et al. Effects of FK 506 on human hepatic microsomal cytochrome P-450-dependent drug metabolism in vitro. 1991 Transplant. Proc. pmid:1721276
Moochhala SM et al. Inhibition of drug metabolism in rat and human liver microsomes by FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1721277
Zeevi A et al. In vitro assessment of FK 506 immunosuppressive activity in transplant patients. 1991 Transplant. Proc. pmid:1721307
Katz HR et al. Mast cell biochemical and functional heterogeneity. 1991 Transplant. Proc. pmid:1721308
de Paulis A et al. Antiinflammatory effect of FK 506 on human basophils. 1991 Transplant. Proc. pmid:1721309
Su MS and Semerjian A Activation of transcription factor NF kappa B in Jurkat cells is inhibited selectively by FK 506 in a signal-dependent manner. 1991 Transplant. Proc. pmid:1721310
Shaw BW et al. FK 506 for rescue treatment of acute and chronic rejection in liver allograft recipients. 1991 Transplant. Proc. pmid:1721338
McDiarmid SV et al. FK 506 rescue therapy in liver transplantation: outcome and complications. 1991 Transplant. Proc. pmid:1721339
Rucay P et al. FK 506 rescue therapy for refractory acute rejection in five liver recipients. 1991 Transplant. Proc. pmid:1721340
Macleod AM and Thomson AW FK 506: an immunosuppressant for the 1990s? 1991 Lancet pmid:1702172
Reding R et al. Compassionate use of FK 506 in pediatric liver transplantation: a pilot study. 1991 Transplant. Proc. pmid:1721341
Wijnen RM et al. Toxicity of FK 506 in the cynomolgus monkey: noncorrelation with FK 506 serum levels. 1991 Transplant. Proc. pmid:1721371
Venkataramanan R et al. Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1703355
Fung JJ et al. Adverse effects associated with the use of FK 506. 1991 Transplant. Proc. pmid:1721372
Omar G et al. FK 506 inhibition of cyclosporine metabolism by human liver microsomes. 1991 Transplant. Proc. pmid:1703356
Hebert MF et al. Efficacy and toxicity of FK 506 for the treatment of resistant rejection in liver transplant patients. 1991 Transplant. Proc. pmid:1721373
Eiras G et al. Effects of FK 506 and cyclosporine on T-cell activation: integrin-mediated adhesion of T cells, proliferation, and maturation of cytotoxic T cells. 1991 Transplant. Proc. pmid:1703357
Clinicopathological evaluation of kidney transplants in patients given a fixed dose of FK 506. Japanese FK 506 Study Group. 1991 Transplant. Proc. pmid:1721374
Christians U et al. Measurement of FK 506 by HPLC and isolation and characterization of its metabolites. 1991 Transplant. Proc. pmid:1703358
Morrisett JD et al. Effect of FK 506 and cyclosporine on plasma cholesterol levels in rabbits. 1991 Transplant. Proc. pmid:1721402
Jacobs TW et al. The effect of FK 506, cyclosporine A, and cyclosporine G on serum 1,25-dihydroxyvitamin D levels. 1991 Transplant. Proc. pmid:1721403
Abu-Elmagd KM et al. Acute hemolytic anemia in liver and bone marrow transplant patients under FK 506 therapy. 1991 Transplant. Proc. pmid:1721404
Adams CK and Famili P A study of the effects of the drug FK 506 on gingival tissues. 1991 Transplant. Proc. pmid:1721405
Wu GD et al. FK 506 inhibits the development of transplant arteriosclerosis. 1991 Transplant. Proc. pmid:1721433
Kitahara S et al. Lymphoproliferative disorders after FK 506. 1991 Lancet pmid:1708846
Kobayashi N et al. Effect of FK 506 on abdominal organ cluster transplantation in pigs. 1991 Transplant. Proc. pmid:1721434
Holechek MJ Medication review: FK 506. 1991 ANNA J pmid:1708982
Wada H et al. An attempt to induce tolerance to skin grafts in congenic mice with FK 506. 1991 Transplant. Proc. pmid:1721435
Michnick SW et al. Solution structure of FKBP, a rotamase enzyme and receptor for FK506 and rapamycin. 1991 Science pmid:1709301
Kuroki H et al. Synergistic effect of FK 506 and donor-specific blood transfusion on rat skin but not on composite tissue (limb) allograft survival. 1991 Transplant. Proc. pmid:1721436
Van Duyne GD et al. Atomic structure of FKBP-FK506, an immunophilin-immunosuppressant complex. 1991 Science pmid:1709302
Armitage JM et al. Preliminary experience with FK506 in thoracic transplantation. 1991 Transplantation pmid:1713363
Lorber MI et al. A comparison of in vivo responses to cyclosporine, FK506, and rapamycin following allogeneic immune challenge. 1991 Transplantation pmid:1713364
Abu-Elmagd K et al. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. 1991 Transplantation pmid:1713365
Matsuura T et al. [Experimental studies on the mode of action of cyclosporine and FK506 assessed by proliferation response of human cloned T lymphocytes]. 1991 Hinyokika Kiyo pmid:1721767
Takada K et al. Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. 1991 J. Pharmacobio-dyn. pmid:1713626
Morris PJ Cyclosporine, FK-506 and other drugs in organ transplantation. 1991 Curr. Opin. Immunol. pmid:1721824
Lhoëst G et al. Isolation and mass spectrometric identification of five metabolites of FK-506, a novel macrolide immunosuppressive agent, from human plasma. 1991 Pharm Acta Helv pmid:1722046
Nicoletti F et al. FK-506 prevents diabetes in diabetes-prone BB/Wor rats. 1991 Int. J. Immunopharmacol. pmid:1722192
Stötter H and Lotze MT Human lymphokine-activated killer cell activity. Role of IL-2, IL-4, and IL-7. 1991 Arch Surg pmid:1726819
Karlsson H and Nässberger L FK506 lacks the ability to inhibit expression of interleukin-2 receptor beta-chain on human lymphocytes. 1991 J Clin Lab Immunol pmid:1726895